In aggregates, a high frequency of activating BRAF mutations (80%) was identified in nevi, indicating that activating BRAF mutations occurs early during melanoma progression [122], an idea supported by recent findings showing that the BRAFV600E mutation was present in the majority of, if not all of, melanocytes in the BRAFV600E nevi examined [123]. This evidence concerns the gene BRAF and melanoma.